All News

lupus.nephritis.immunofluorescence.jpg

Trends and Innovations in Lupus Nephritis Clinical Trials

Jack Cush, MD

Xu et al. from Shanghai University have written an analysis of global lupus nephritis (LN) clinical trials and call for innovation.

Read Article
RheumNow Podcast square

Quiz Talk (5.22.2026)

Jack Cush, MD

Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.

Read Article
H2H.BKZ.RZB

BE BOLD Week 16 data - Bimekizumab vs. Risankizumab in PsA

Jack Cush, MD

UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6.

Read Article
undifferentiated,arthritis,early,RA

ABA versus HCQ in Palindromic Rheumatism

Jack Cush, MD

Palindromic rheumatism may develop rheumatoid arthritis (RA) and could be an at-risk population. A pilot trial compared abatacept (ABA) versus hydroxychloroquine and demonstrated ABA reduces RA development in a 2 year study. 

Read Article
RheumNow Podcast square

Infectious Rheumatology (5.15.2026)

Jack Cush, MD

Dr. Jack Cush discusses his favorite journal articles from the past week on RheumNow.com.

Read Article
SI AS SpA ACR

Another IL-17A inhibitor (Vunakizumab) for active Ankylosing Spondylitis

Jack Cush, MD

Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective and

Read Article
lupus.skinbx.jpg

Toll-Like Receptor Drugs Effective in Cutaneous Lupus

MedPage Today

Enpatoran, an investigational oral drug that inhibits Toll-like receptors (TLR) 7 and 8, was superior to placebo in relieving lupus skin manifestations in a dose-finding phase II trial.

Read Article
Canada’s Drug Agency (CDA-AMC) has recommended Gazyva (obinutuzumab) for public reimbursement. This recommendation is for the treatment of adult patients with active lupus nephritis who are receiving standard therapy https://t.co/TC1MVAShdC https://t.co/flXVmLwGtW

Links:

Dr. John Cush RheumNow ( View Tweet)
Let me give you an example of where there is no gov intervention, and the impact on brand drug pricing. When a brand manufacturer sells a drug to one of the big 3 drug distributors that control more than 90 pct of their market, those multi hundred billion dollar distributors

Mark Cuban mcuban ( View Tweet)

FDA has approved benralizumab (Fasenra) for the treatment of adult and pediatric patients w/ hypereosinophilic syndrome (HES); based on the NATRON Phase III trial https://t.co/7se6qLsQoP https://t.co/64wC94hTTq

Links:

Dr. John Cush RheumNow ( View Tweet)
Kissei Pharmaceuticals announced 20 deaths related to receiving avacopan (Tavneos), a vasculitis drug sold by the firm in Japan. Drug was released in June 2022, since its been given to ~8,500 pts. Avacopan safety is being reviewed by FDA with Amgen. https://t.co/ri0nROCL5U https://t.co/jbksrWMFwI

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved a dosing update for burosumab-twza (Crysvita, Kyowa Kirin) to allow for increased dose and frequency when needed in adults with X-linked hypophosphatemia (XLH). https://t.co/EPyp6tDsaf https://t.co/1HEaQRk9BR

Links:

Dr. John Cush RheumNow ( View Tweet)
Goofy study of the month! (pub in JAMA!) RCT 170 adults w/ chronic LBP + MRI disc herniation found that amoxicillin-clavulanate, 500 mg/125 mg bid x 3 mos did not improve pain at 3 or 12 mos (vs PBO). Whatha... https://t.co/njrw6itAP8 https://t.co/CW2ssNPxf1

Links:

Dr. John Cush RheumNow ( View Tweet)
Israel study 264,858 pregnancies- 1st trimester NSAID exposure had no risk of congenital malformations (MCM). 8% exposed vs unexposed: overall MCM 8.2% v 7%; aRR 0.99). MCMs not incr = MSK, CV, CNS, cleft palate, GI, GU, nonsignif MSM aRR from 0.77- 1.05 https://t.co/ytYhBFl44o https://t.co/1fq4D1KykM

Links:

Dr. John Cush RheumNow ( View Tweet)
Medical Economics reports only 18% MDs practiced in MD-owned settings, a new low. By Jan '26 hospitals or corporate employment rose to 550,494 & independent MDs fell to 120,900 https://t.co/l0tt3yO9kt https://t.co/pkgmHFPjE1

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved benralizumab (Fasenra) for the treatment of adult and pediatric patients w/ hypereosinophilic syndrome (HES); based on the NATRON Phase III trial https://t.co/qqPsjhUClP https://t.co/lCZNoTh9fv

Links:

Dr. John Cush RheumNow ( View Tweet)
Branebrutinib (Bruton's tyrosine kinase inhibitor) was studied in phase 2 RCT of 85 RA pts for 12 weeks and was safe but failed to achieve an ACR50 response (19% BTK vs 33% PBO; p=0·16). https://t.co/gTjLJm9iIW https://t.co/GN9p1P8ZNJ

Links:

Dr. John Cush RheumNow ( View Tweet)
UCB has aquired Candid Therapeutics for $2 billion; plan to lead in autoimmune dz by acquiring cizutamig - a T cell engager. Its been studied in >100 pts, including early Global Phase 2 RCTs of myasthenia gravis & ILD. https://t.co/xz4uEhvxu6 https://t.co/6FS1riLecW

Links:

Dr. John Cush RheumNow ( View Tweet)
No link between pregnancy tylenol & autism. JAMA Pediatrics data from 1.5 million Danish children( 1997 -2022); ~2% were tylenol exposed during preg. 2% of these Dx w/ Dx w/ autism (vs. 3% not exposed) https://t.co/Pp1tE54Dic https://t.co/qu61jKolpN

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has published final guidance on Postapproval Pregnancy Safety Studies; how to study outcomes in pregnant women exposed to drugs & biologics- updates on registries,statistical methods, complementary studies, rare Rx exposures https://t.co/NWxrgB0dPQ https://t.co/ckyaJ07MQ0

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×